Medical device and MedTech insights, news, tips and more

Access Vascular, Inc., a company addressing the most common and costly venous access complications, today announced it has closed on a Series B round of financing. TVM Capital Life Science led the round with a $15 million commitment, with existing investors also participating.

Access Vascular has developed a proprietary biomaterial platform that is both hydrophilic and lubricious, and has incorporated this material into two commercially-available venous access devices, the HydroPICC Peripherally Inserted Central Catheter and HydroMID Midline Catheter. In vitro studies have shown that this biomaterial technology results in an average of 97% less thrombus accumulation on its surface compared to a standard polyurethane catheter.

The new financing will be used to generate post-market data on its two commercial devices designed to reduce thrombus accumulation and catheter occlusions, expand its portfolio of devices, and commercialize the portfolio of products.

“We are extremely pleased to partner with TVM Capital Life Science, a world-class venture capital firm with an extensive track record of successfully investing in, and supporting, early-stage commercial companies in order to maximize their growth potential,” said Access Vascular CEO James Biggins. “Their commitment to partnering with Access Vascular validates our conviction to continue solving critical issues in the vascular access space with our growing portfolio of proprietary technologies.”

“We believe that Access Vascular’s products can address the biggest unmet needs in the vascular access space. Their unique biomaterial technology shows a substantial reduction in the body’s biological response to the catheter, minimizing potential complications,” said Luc Marengere, PhD, Managing Partner, TVM Capital Life Science. “With our partnership, Access Vascular will be able to bring their innovative solutions to more patients, with the intent to improve outcomes and deliver higher procedural acuity.”

As part of the investment, Managing Partner Dr. Luc Marengere and Principal Dr. Alexandra MacLean, with TVM Capital Life Science, will join the Access Vascular Board of Directors.

About Access Vascular

Access Vascular was founded in 2015 to address the most common and costly complications of intravenous therapy: infection, thrombosis and phlebitis. The company is developing a suite of venous access devices made from patented biomaterials which are highly biocompatible and are capable of long-term thrombus resistance.

See Full Press Release at the Source: Access Vascular, Inc. Secures $20 Million in Series B Financing | Business Wire

Press Release by: Access Vascular

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.